Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Aurinia Pharmaceuticals Inc - Common Shares (NQ:AUPH)

15.49 +0.14 (+0.91%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Aurinia Pharmaceuticals Inc - Common Shares

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
News headline image
AURINIA PHARMACEUTICALS INC (NASDAQ:AUPH) Passes Louis Navellier's Strict Growth Stock Screen ↗
Aurinia Pharmaceuticals (AUPH) exemplifies a top growth stock, showing explosive earnings growth, soaring cash flow, and consistent earnings surprises. 
Via Chartmill
News headline image
Earnings Scheduled For November 4, 2025 ↗
 
Via Benzinga
News headline image
Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2025 and Provides Update on Recent Business Progress
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
A Peek at Aurinia Pharmaceuticals's Future Earnings ↗
 
Via Benzinga
News headline image
FDA Drug Chief George Tidmarsh Resigns After Allegations Of Power Misuse ↗
FDA drug center head George Tidmarsh resigned after accusations of misusing power to harm a former business associate. He denies wrongdoing. 
Via Benzinga
Aurinia Pharma Stands By Lupus Drug After FDA Official’s Retracted Post Sparks 16% Selloff — Retail Stays Bullish On Recovery ↗
Via Stocktwits
News headline image
Earnings Scheduled For July 31, 2025 ↗
 
Via Benzinga
News headline image
Aurinia Pharmaceuticals to Report Financial Results for the Three and Nine Months Ended September 30, 2025 and Provide Update on Recent Business Progress on November 4, 2025
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
FDA Turmoil Spills Over To Aurinia Pharma As Lawsuit Targets Ex-Drug Review Chief — Retail Traders Cry ‘Stock Manipulation’ ↗
Things got murkier at the FDA’s drug evaluation agency as its acting director stepped down, alleging that a new drug approval program injected politics, superseding decisions based on science. 
Via Stocktwits
Topics Lawsuit
News headline image
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Shows Strong Growth Traits in Fundamental Analysis ↗
Discover Aurinia Pharmaceuticals (AUPH), a top growth stock with explosive earnings, soaring revenue, and high ROE, using Louis Navellier's proven investment strategy. 
Via Chartmill
News headline image
Aurinia Announces Upcoming Presentations of New Data on LUPKYNIS® at American College of Rheumatology Convergence and American Society of Nephrology Kidney Week 2025
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
Aurinia Responds to Now Retracted LinkedIn Post
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
Gainers SciSparc (NASDAQ: SPRC) shares increased by 28.2% to $5.68 during Monday's after-market session. The company's market cap stands at $2.2 million. 
Via Benzinga
News headline image
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Passes Louis Navellier's Growth Screen ↗
Aurinia Pharmaceuticals (AUPH) is a top growth stock pick based on Louis Navellier's strategy, showing explosive earnings growth, strong sales momentum, and rising profit margins. 
Via Chartmill
News headline image
United Therapeutics Price Strength Rating Jumps After Its Stock Soared 33% Last Week On Positive Drug Test Results ↗
United Therapeutics also boasts a terrific 96 Composite Rating. The Composite score combines five separate proprietary ratings into one. 
Via Investor's Business Daily
Topics ETFs
News headline image
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Shows Strong Growth Metrics and Earnings Momentum ↗
Aurinia Pharma (AUPH) shows strong growth momentum with surging earnings, impressive sales growth, and major margin expansion, making it a top pick for growth investors. 
Via Chartmill
News headline image
Argenx Stock Hits Record High After Reporting 664% Earnings Surge; This Rating Upgraded ↗
Additionally, the IBD SmartSelect Composite Rating for Argenx stock rose from 94 to a near best 96 Tuesday. 
Via Investor's Business Daily
Topics ETFs
News headline image
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Fits Louis Navellier’s High-Growth Stock Criteria ↗
Louis Navellier's growth strategy highlights Aurinia Pharmaceuticals (AUPH) for strong earnings momentum, rising revenue, and solid ROE—key traits for high-growth stock success. 
Via Chartmill
News headline image
Gilead Sciences Reports Earnings Thursday. Can The Highly Ranked Drugmaker Beat Its 237% Profit Surge Last Quarter? ↗
The upgraded score means Gilead is now outperforming 96% of all stocks in terms of the most important stock-picking criteria. 
Via Investor's Business Daily
News headline image
Aurinia (AUPH) Q2 Revenue Jumps 22% ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2025
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) – A Strong Candidate for Growth Investors ↗
Aurinia Pharmaceuticals (AUPH) meets key growth criteria from Louis Navellier’s strategy, with strong earnings, sales growth, and improving margins. The stock shows solid financial health and... 
Via Chartmill
News headline image
Aurinia Pharmaceuticals to Release Second Quarter 2025 Financial and Operational Results on July 31, 2025
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) – A Strong Candidate for Growth Investors ↗
Aurinia Pharmaceuticals (NASDAQ:AUPH) shows strong growth metrics, including surging earnings, revenue, and cash flow, making it a candidate for investors following Louis Navellier’s strategy. 
Via Chartmill
News headline image
Aurinia Announces Positive Results from Phase 1 Study of Aritinercept (AUR200)
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
Retail Bulls Charge Into Aurinia Pharmaceuticals Ahead Of Autoimmune Trial Results ↗
AUR200 targets both BAFF and APRIL, which are key immune system proteins. It is being developed for one large indication and one rare disease. 
Via Stocktwits
News headline image
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) – A Strong Candidate for Growth Investors ↗
Aurinia Pharmaceuticals (AUPH) shows strong growth, earnings momentum, and improving margins, making it a candidate for investors following Louis Navellier’s strategy. 
Via Chartmill
News headline image
US Stocks Likely To Open On A Mixed Note: 'Nothing Good Happens Above A 5% Yield,' Says Expert ↗
U.S. stock futures were fluctuating on Friday after a mixed close on Thursday. Futures of benchmark indices were mixed in premarket. 
Via Benzinga
News headline image
Aurinia Pharmaceuticals to Host Conference Call to Discuss AUR200 Phase 1 Study Results on June 30, 2025
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
New AURORA 1 Analysis: LUPKYNIS-Based Triple Immunosuppressive Therapy Yields Deep Proteinuria Reduction in Lupus Nephritis
From Aurinia Pharmaceuticals Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.